In the offering, the Boca Raton, Fla.-based floated 2.2 million shares at $6.80 apiece, for gross proceeds just shy of $15.0 million. The offering also includes a 30-day underwriter’s option to purchase an additional 330,882 shares for the same price, which would pull in another $2.3 million if exercised in full.
Sensus said it plans to use net proceeds for general corporate purposes, including R&D, expansion of product lines and roll-out of new products.
B. Riley FBR was lead underwriter and sole book-runner for the offering, with Craig-Hallum Capital Group and Roth Capital Partners as co-managers for the offering and Maxim Group as financial advisor.
Last month, Sensus Healthcare said that it won FDA 510(k) clearance for its SRT-100+ next-gen superficial radiation therapy system.
Registration is open for DeviceTalks Boston! Join us on June 5-6, 2019, as we explore the trends and technology that are shaping the future of the medical device industry.